Life sciences developer Avacta Group plc has named Neil Bell the new Chief Development Officer of its subsidiary, Avacta Life Sciences, with immediate effect. Mr. Bell will oversee pre-clinical and early clinical development of the company’s pre|CISION pro-drugs and Affimer immunotherapies.
“I am absolutely delighted that Neil is joining Avacta as Chief Development Officer to build and lead the development team to take a pipeline of innovative cancer therapies into the clinic over the next few years; therapies that have the potential to significantly enhance cancer patients’ lives,” said Avacta Group Chief Executive Dr. Alastair Smith.
Mr. Bell has more than 30 of years expertise in drug development, with a number of senior roles in global pharmaceuticals and biotech companies. He most recently served as Senior Vice President, Head of Global Clinical Operations at cell and gene therapy company Autolus.
“I am delighted to join the therapeutics team at Avacta Life Sciences at such an exciting time in its growth trajectory and where I believe the company has significant opportunity to build a successful and agile clinical stage biopharmaceutical organisation with the capability to maximise its early development oncology assets for the ultimate benefit of patients,” said Mr. Bell.